Modeling and Simulation in the Context of Health Technology Assessment: Review of Existing Guidance, Future Research Needs, and Validity Assessment
暂无分享,去创建一个
Amy Earley | Denish Moorthy | Esther E Avendano | John B. Wong | Thomas A Trikalinos | Jeffrey Chan | Ethan M Balk | Issa J Dahabreh | T. Trikalinos | J. Wong | E. Balk | I. Dahabreh | A. Earley | Jeffrey A Chan | E. Avendano | D. Moorthy
[1] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[2] Ross D. Shachter,et al. A Bayesian Method for Synthesizing Evidence: The Confidence Profile Method , 1990, International Journal of Technology Assessment in Health Care.
[3] Uwe Siebert,et al. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[4] J Mullahy. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. , 1996, Medical care.
[5] M. Drummond,et al. Standardizing Methodologies for Economic Evaluation in Health Care: Practice, Problems, and Potential , 1993, International Journal of Technology Assessment in Health Care.
[6] Uwe Siebert,et al. Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure , 2011, PharmacoEconomics.
[7] Uwe Siebert,et al. Systematic assessment of decision models in Parkinson's disease. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] Nicholas J Wald,et al. Teleoanalysis: combining data from different types of study , 2003, BMJ : British Medical Journal.
[9] Michael Willis,et al. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM) , 2013, Journal of medical economics.
[10] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[11] M Sculpher,et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.
[12] M C Weinstein,et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. , 1997, PharmacoEconomics.
[13] Gail Gong,et al. Pseudo Maximum Likelihood Estimation: Theory and Applications , 1981 .
[14] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] Alex J. Sutton,et al. Evidence Synthesis for Decision Making Inconsistency in Networks of Evidence Based on Randomized Controlled Trials. , 2013 .
[16] Kristian Bolin,et al. Economic Evaluation of Smoking-Cessation Therapies , 2012, PharmacoEconomics.
[17] Jonathan Karnon,et al. Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[18] Natasha K Stout,et al. Empirically evaluating decision-analytic models. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] Isao Kamae,et al. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] Rob Deardon,et al. Goodness-of-fit measures for individual-level models of infectious disease in a Bayesian framework. , 2011, Spatial and spatio-temporal epidemiology.
[21] Maarten J. Postma,et al. Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes , 2012, PharmacoEconomics.
[22] Amy J Grizzle,et al. Industry's Perception of Presenting Pharmacoeconomic Models to Managed Care Organizations , 2003, Journal of managed care pharmacy : JMCP.
[23] Eloise E Kaizar. Estimating treatment effect via simple cross design synthesis , 2011, Statistics in medicine.
[24] Josephine Mauskopf,et al. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] Dimitris Bertsimas,et al. On the Efficiency-Fairness Trade-off , 2012, Manag. Sci..
[26] Sean D Sullivan,et al. Quality of clinical and economic evidence in dossier formulary submissions. , 2007, The American journal of managed care.
[27] Chung Yin Kong,et al. Development, Calibration, and Validation of a U.S. White Male Population-Based Simulation Model of Esophageal Adenocarcinoma , 2010, PloS one.
[28] David J Spiegelhalter,et al. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.
[29] D J Spiegelhalter,et al. Approximate cross‐validatory predictive checks in disease mapping models , 2003, Statistics in medicine.
[30] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 6: Embedding Evidence Synthesis in Probabilistic Cost-effectiveness Analysis. , 2013 .
[31] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 5: The Baseline Natural History Model. (5), , 2013 .
[32] K. Schittkowski,et al. NONLINEAR PROGRAMMING , 2022 .
[33] C C Blackmore,et al. Methodologic evaluation of the radiology cost-effectiveness literature. , 1997, Radiology.
[34] R. Kane,et al. Decision and Simulation Modeling in Systematic Reviews , 2013 .
[35] E Goyder,et al. A review and critique of modelling in prioritising and designing screening programmes. , 2007, Health technology assessment.
[36] Milton C. Weinstein,et al. Incorporating Calibrated Model Parameters into Sensitivity Analyses , 2012, PharmacoEconomics.
[37] Jonathan Karnon,et al. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective , 2008, The European Journal of Health Economics.
[38] G. Seage,et al. Individual-Based Simulation Models of HIV Transmission: Reporting Quality and Recommendations , 2013, PloS one.
[39] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 1: Introduction. Medical Decision Making, , 2013 .
[40] George W. Torrance,et al. The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals , 1999, PharmacoEconomics.
[41] Simon Dixon,et al. Testing the Validity of Cost-Effectiveness Models , 2000, PharmacoEconomics.
[42] Katarzyna Kolasa,et al. What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008? , 2011, International Journal of Technology Assessment in Health Care.
[43] Jennifer A. Roberts,et al. Economic Evaluation of Diagnostic Technology: Methodological Challenges and Viable Solutions , 1997, International Journal of Technology Assessment in Health Care.
[44] S W Duffy,et al. Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility. , 2002, Journal of cancer epidemiology and prevention.
[45] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.
[46] Stuart Brody,et al. Plausible and implausible parameters for mathematical modeling of nominal heterosexual HIV transmission. , 2007, Annals of epidemiology.
[47] D Menon,et al. Canada's new guidelines for the economic evaluation of pharmaceuticals. , 1996, Medical care.
[48] David M. Eddy,et al. Meta-analysis by the confidence profile method , 1992 .
[49] Milton C. Weinstein,et al. Recommendations for Reporting Cost-effectiveness Analyses , 1996 .
[50] D B Evans,et al. Development of WHO guidelines on generalized cost-effectiveness analysis. , 2000, Health economics.
[51] Jill M Ferdinands,et al. Obstructive Lung Disease Models: What Is Valid? , 2008, COPD.
[52] Johan L. Severens,et al. Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands , 2012, PharmacoEconomics.
[53] Andrea Manca,et al. Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies , 2005, International Journal of Technology Assessment in Health Care.
[54] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[55] Suzanne L. West,et al. CLINICAL HETEROGENEITY IN SYSTEMATIC REVIEWS AND HEALTH TECHNOLOGY ASSESSMENTS: SYNTHESIS OF GUIDANCE DOCUMENTS AND THE LITERATURE , 2012, International Journal of Technology Assessment in Health Care.
[56] H. D. de Vet,et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria , 2005, International Journal of Technology Assessment in Health Care.
[57] Anna García-Altés,et al. Spanish recommendations on economic evaluation of health technologies , 2010, The European Journal of Health Economics.
[58] S. Goodman,et al. Reproducible Research: Moving toward Research the Public Can Really Trust , 2007, Annals of Internal Medicine.
[59] R. Platt,et al. Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.
[60] Janneke P C Grutters,et al. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[61] S. Chick,et al. A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.
[62] A. Gelman. A Bayesian Formulation of Exploratory Data Analysis and Goodness‐of‐fit Testing * , 2003 .
[63] G Scott Gazelle,et al. Calibration of disease simulation model using an engineering approach. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[64] Cathal Walsh,et al. Bayesian Calibration of a Natural History Model with Application to a Population Model for Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.
[65] Kyle R. Douglas-Mankin,et al. Hydrologic and Water Quality Models: Use, Calibration, and Validation , 2012 .
[66] Joseph Lau,et al. Decision-Analytic Modeling to Evaluate Benefits and Harms of Medical Tests: Uses and Limitations , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.
[67] Jonathan Karnon,et al. Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions , 2011, PharmacoEconomics.
[68] M J Nuijten,et al. Reporting format for economic evaluation. Part II: Focus on modelling studies. , 1998, PharmacoEconomics.
[69] Iris Lansdorp-Vogelaar,et al. A Systematic Comparison of Microsimulation Models of Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.
[70] L. Mantovani,et al. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics. , 1995, PharmacoEconomics.
[71] P Barton,et al. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. , 2009, Health technology assessment.
[72] Javier Soto,et al. HEALTH ECONOMIC EVALUATIONS USING DECISION ANALYTIC MODELING , 2002, International Journal of Technology Assessment in Health Care.
[73] Uwe Siebert,et al. EBM, HTA, and CER: clearing the confusion. , 2010, The Milbank quarterly.
[74] F A Sonnenberg,et al. Toward a Peer Review Process for Medical Decision Analysis Models , 1994, Medical care.
[75] E. Lee,et al. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[76] J Chilcott,et al. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. , 2010, Health technology assessment.
[77] M Sculpher,et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.
[78] Jonathan Karnon,et al. Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases , 2013, Applied Health Economics and Health Policy.
[79] A S Detsky,et al. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. , 1993, PharmacoEconomics.
[80] S. Zeger,et al. Latent Class Model Diagnosis , 2000, Biometrics.
[81] F. Pang,et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.
[82] Daniela De Angelis,et al. Mathematical models for the study of HIV spread and control amongst men who have sex with men , 2011, European Journal of Epidemiology.
[83] C. Bell,et al. The Quality of Reporting in Published Cost-Utility Analyses, 19761997 , 2000, Annals of Internal Medicine.
[84] Murray Krahn,et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[85] Yola Moride,et al. Validation of a decision model for preventive pharmacological strategies in postmenopausal women , 2004, European Journal of Epidemiology.
[86] A E Ades,et al. Markov Chain Monte Carlo Estimation of a Multiparameter Decision Model: Consistency of Evidence and the Accurate Assessment of Uncertainty , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[87] Günther Zauner,et al. Appropriate Evidence Sources for Populating Decision Analytic Models Within Health Technology Assessment (HTA): A Systematic Review of HTA Manuals and Health Economic Guidelines , 2013 .
[88] A E Ades,et al. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. , 2006, Health economics.
[89] C. Gouriéroux,et al. PSEUDO MAXIMUM LIKELIHOOD METHODS: THEORY , 1984 .
[90] Xiao-Li Meng,et al. POSTERIOR PREDICTIVE ASSESSMENT OF MODEL FITNESS VIA REALIZED DISCREPANCIES , 1996 .
[91] Michael T French,et al. Economic evaluation of telemedicine: review of the literature and research guidelines for benefit-cost analysis. , 2009, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[92] G A Colditz,et al. Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.
[93] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.
[94] Vivek Pawar,et al. Methods of Model Calibration , 2012, PharmacoEconomics.
[95] R. Willke,et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[96] Carol Bennett,et al. Reporting guidelines for modelling studies , 2012, BMC Medical Research Methodology.
[97] W. Ungar,et al. The Pediatric Quality Appraisal Questionnaire: an instrument for evaluation of the pediatric health economics literature. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[98] Milton C. Weinstein,et al. Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.
[99] Alex J. Sutton,et al. Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment , 2011 .
[100] J. Hay,et al. Panel 2: methodological issues in conducting pharmacoeconomic evaluations--modeling studies. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[101] C. Mullins,et al. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. , 2002, PharmacoEconomics.
[102] Paul C Langley. Modeling for health care and other policy decisions: uses, roles, and validity. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[103] Uwe Siebert,et al. Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia , 2014, Applied Health Economics and Health Policy.
[104] B Lovatt,et al. The United Kingdom guidelines for the economic evaluation of medicines. , 1996, Medical care.
[105] J B Wong,et al. Validating a Markov Model of Treatment for Hepatitis C Virus-related Hepatocellular Carcinoma , 2008, Methods of Information in Medicine.
[106] Christian Weber,et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[107] M C Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[108] Michel Huybrechts,et al. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[109] Nicky J Welton,et al. Multiparameter evidence synthesis in epidemiology and medical decision-making , 2008, Journal of health services research & policy.
[110] D. Pieper,et al. Methods of international health technology assessment agencies for economic evaluations- a comparative analysis , 2013, BMC Health Services Research.
[111] J. Mason,et al. The Generalisability of Pharmacoeconomic Studies , 1997, PharmacoEconomics.
[112] J. Savarino,et al. Bayesian Calibration of Microsimulation Models , 2009, Journal of the American Statistical Association.
[113] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 7 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[114] G Scott Gazelle,et al. Chapter 9: The MGH‐HMS Lung Cancer Policy Model: Tobacco Control Versus Screening , 2012, Risk analysis : an official publication of the Society for Risk Analysis.
[115] E. Chelimsky,et al. Cross-design Synthesis: A New Form of Meta-analysis for Combining Results from Randomized Clinical Trials and Medical-practice Databases , 1993, International Journal of Technology Assessment in Health Care.
[116] J L Severens,et al. Economic evaluation of diagnostic tests. A review of published studies. , 1999, International journal of technology assessment in health care.
[117] Mark Jit,et al. Calibration of Complex Models through Bayesian Evidence Synthesis , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.
[118] Richard G. White,et al. Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.
[119] A Liberati,et al. EUR-ASSESS Project Subgroup Report on Methodology: Methodological Guidance for the Conduct of Health Technology Assessment , 1997, International Journal of Technology Assessment in Health Care.
[120] Josephine Mauskopf,et al. Methodological and Conduct Principles for Pharmacoeconomic Research , 1995, PharmacoEconomics.
[121] John Nixon,et al. Can economic evaluations be made more transferable? , 2005, The European Journal of Health Economics.
[122] Carla E. Brodley,et al. Semi-automated screening of biomedical citations for systematic reviews , 2010, BMC Bioinformatics.
[123] Sean D Sullivan,et al. Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies , 2003, Medical care.
[124] Mark Sculpher,et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[125] J. Caro,et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[126] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine , 1997 .
[127] C. Mullins,et al. Emerging standardization in pharmacoeconomics. , 1998, Clinical therapeutics.
[128] Simon G Thompson,et al. Uncertainty and validation of health economic decision models. , 2009, Health economics.
[129] Natasha K. Stout,et al. Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines , 2012, PharmacoEconomics.
[130] Mark Sculpher,et al. Common Methodological Flaws in Economic Evaluations , 2005, Medical care.
[131] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .
[132] S Gallivan,et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK , 2006, British Journal of Cancer.
[133] R. Peng. Reproducible Research in Computational Science , 2011, Science.
[134] David M. Eddy,et al. The Confidence Profile Method: A Bayesian Method for Assessing Health Technologies , 1989, Oper. Res..
[135] Sean D Sullivan,et al. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[136] Thomas Mittendorf,et al. Methods for determining cost-benefit ratios for pharmaceuticals in Germany , 2007, The European Journal of Health Economics.
[137] Ross D. Shachter,et al. An Introduction to a Bayesian Method for Meta-analysis , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.
[138] Theo Stijnen,et al. Apparent and Internal Validity of a Monte Carlo–Markov Model for Cardiovascular Disease in a Cohort Follow-up Study , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[139] D. Legates,et al. Evaluating the use of “goodness‐of‐fit” Measures in hydrologic and hydroclimatic model validation , 1999 .
[140] A Gafni,et al. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. , 1999, Journal of evaluation in clinical practice.
[141] Uwe Siebert,et al. Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease , 2012, PharmacoEconomics.
[142] Jonathan Karnon,et al. A Critique and Impact Analysis of Decision Modeling Assumptions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[143] Karl Claxton,et al. Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.
[144] Paul Meissner,et al. A New Taxonomy for Stakeholder Engagement in Patient-Centered Outcomes Research , 2012, Journal of General Internal Medicine.
[145] Jeffrey G. Arnold,et al. Model Evaluation Guidelines for Systematic Quantification of Accuracy in Watershed Simulations , 2007 .
[146] Simon Capewell,et al. Coronary heart disease policy models: a systematic review , 2006, BMC public health.
[147] James J. Heckman,et al. The Empirical Foundations of Calibration , 1996 .
[148] N. Welton,et al. Estimation of Markov Chain Transition Probabilities and Rates from Fully and Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[149] B R Luce,et al. Methods of cost-effectiveness analysis: areas of consensus and debate. , 1995, Clinical therapeutics.
[150] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[151] J. Elston,et al. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. , 2009, Health technology assessment.
[152] Suzy Paisley. Classification of evidence in decision-analytic models of cost-effectiveness: a content analysis of published reports. , 2010, International journal of technology assessment in health care.
[153] Ben S Cooper,et al. Confronting models with data. , 2007, The Journal of hospital infection.